COVID-19 Archives - Page 13 of 16

Markets

BTIG starts Fulgent Genetics at buy; PT $20

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a “buy” rating and $20 price target. The stock closed at $16.06 on May 28. Fulgent is a genetic testing service provider that has delivered more than...

May 29, 2020

Markets

Dawson James starts Sorrento Therapeutics at buy; PT $24

Dawson James Securities launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $24 price target. The stock closed at $5.07 on May 22. Analyst Jason Kolbert writes that Sorrento’s STI-1499...

May 26, 2020

Developments

Maxim ups Co-Diagnostics to buy; PT $30

Maxim Group upgraded Co-Diagnostics (NASDAQ:CODX) to “buy” from “hold” with a $30 price target, saying that COVID-19 testing has been transformative for the company. The stock closed at $18.85 on May 19. Co-Diagnostics...

May 20, 2020

Developments

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

Closely-held PharmaJet’s needle-free injection system will be used to deliver a SARS-CoV mRNA vaccine being developed by Abnova, the world’s largest antibody vaccine manufacturer. “Our system has been found to improve...

May 19, 2020

Feature

Spring Bank Pharma may expand R&D with potential COVID-19 agents

After abruptly ending its hepatitis B virus program in January, Spring Bank Pharmaceuticals (NASDAQ:SBPH) is in the early stages of examining whether its family of RIG-I agonists have the potential to attack SARS-CoV-2...

May 19, 2020

Feature

COVID-19 presents opportunities and challenges for Field Trip Psychedelics

Despite delays in dosing of patients at its Toronto clinic and building its network of clinics in the U.S. because of COVID-19, closely-held Field Trip Psychedelics is finding opportunities to expand its psychedelic...

May 12, 2020

Markets

Brookline doubles Arcturus Therapeutics PT to $64 from $32

Brookline Capital Markets raised its price target for Arcturus Therapeutics (NASDAQ:ARCT) to $64 from $32, citing positive immunogenicity data for its COVID-19 vaccine. The stock was quoted at $44.88, up $5.65, in...

May 11, 2020

Developments

Kiniksa Pharma updates data from COVID-19, chronic pruritis studies

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported updated data from its open-label study of mavrilimab for the treatment of COVID-19-related pneumonia, as well as its Phase 2 trial for vixarelimab for the treatment of...

May 11, 2020

Developments

FDA clears Pluristem IND for PLX-PAD in COVID-19-related ARDS

Pluristem Therapeutics (NASDAQ:PSTI) received FDA clearance for an IND application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with intramuscular injections of PLX-PAD. ...

May 8, 2020

Developments

Kane Biotech identifies pipeline technologies with potential anti-viral properties

In response to a Canadian COVID-19 Challenges Procurement Program, Kane Biotech (TSXV:KNE) has identified two patented technologies in its existing pipeline that the company believes may have some anti-viral properties...

May 7, 2020

Tag - COVID-19

BTIG starts Fulgent Genetics at buy; PT $20

Dawson James starts Sorrento Therapeutics at buy; PT $24

Maxim ups Co-Diagnostics to buy; PT $30

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

Spring Bank Pharma may expand R&D with potential COVID-19 agents

COVID-19 presents opportunities and challenges for Field Trip Psychedelics

Brookline doubles Arcturus Therapeutics PT to $64 from $32

Kiniksa Pharma updates data from COVID-19, chronic pruritis studies

FDA clears Pluristem IND for PLX-PAD in COVID-19-related ARDS

Kane Biotech identifies pipeline technologies with potential anti-viral properties

General

More